Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
复制标题
患有 II 期雌激素受体阳性乳腺癌的绝经后妇女的内分泌与内分泌加五药化疗的比较。
DOI：
10.1002/1097-0142(19891101)64:9
复制
发表时间：
1989
期刊：
影响因子：
6.2
通讯作者：
McGuire,W
中科院分区：
文献类型：
--
作者：
Pearson,OH;Hubay,CA;Gordon,NH;Marshall,JS;Crowe,JP;Arafah,BM;McGuire,W
绝经后接受改良根治性乳房切除术的II期雌激素受体（ER）阳性乳腺癌患者随机分为两组，一组接受内分泌治疗（他莫昔芬[T]，每日40mg，持续3年），另一组接受内分泌治疗加5种药物化疗（环磷酰胺[C]，甲氨蝶呤[M]， 5 -氟尿嘧啶[F]，长春新碱[V]，强的松[P]， CMFVP，持续1年）。化疗包括口服P（1个月），口服C（12个月），前3个月每周静脉注射MFV， 3个月每两周，6个月每三周。患者于1979年10月至1985年10月进入研究，中位随访时间为55个月。结果显示，在94名绝经后妇女中，与单独接受T治疗的患者相比，接受CMFVPT治疗的患者无病生存率（DFS）显著提高（P= 0.04， log‐rank检验；P= 0.03，多变量分析）。这些结果表明，在绝经后患者中，强化化疗联合T治疗比单独T治疗更有效地延缓复发。
Postmenopausal women who underwent modified radical mastectomy for Stage II, estrogen receptor (ER)‐positive breast cancer were randomized to receive endocrine treatment (tamoxifen [T], 40 mg daily for 3 years) aloneversusendocrine treatment plus five‐drug chemotherapy (Cytoxan [cyclophosphamide, C], methotrexate [M], 5‐fluorouracil [F], vincristine [V], and prednisone [P], CMFVP, for 1 year). Chemotherapy consisted of oral P (1 month), oral C (12 months), and intravenous MFV weekly for the first 3 months, biweekly for 3 months, and triweekly for 6 months. Patients were entered into the study from October 1979, to October 1985, and the median follow‐up is 55 months. Results show that with 94 postmenopausal women, disease‐free survival (DFS) is significantly greater (P= 0.04, log‐rank test;P= 0.03, multivariate analysis) in patients receiving CMFVPT as compared to those receiving T alone. These results suggest that intensive chemotherapy combined with T is more effective in delaying recurrence than T alone in postmenopausal patients.